Kestra Medical TECHNOLOGIES, Ltd. (KMTS) intrinsic value & 10-year financials
Kestra Medical TECHNOLOGIES, Ltd. (KMTS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 3 fiscal years revenue grew 115.0% a year to $59.8M, with an average return on invested capital of 90.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $27.24
- Market cap
- $669.7M
- Revenue (FY2025)
- $59.8M
- Revenue growth (3-yr CAGR)
- 115.0%
- ROIC (10-yr avg)
- 90.9%
- Free cash flow (FY2025)
- -$100.5M
KMTS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $59.8M | -$113.8M | -$5.13 | -$100.5M | -177.8% | 132.5% |
| FY2024 | $27.8M | -$94.1M | -$5.07 | -$84.5M | -305.8% | 49.3% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
KESTRA MEDICAL TECHNOLOGIES, LTD. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
KESTRA MEDICAL TECHNOLOGIES, LTD. has earned high returns on invested capital, averaging 90.9% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
KESTRA MEDICAL TECHNOLOGIES, LTD. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, KESTRA MEDICAL TECHNOLOGIES, LTD. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-170.40 per share.